Cancers | |
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma | |
Andrej Pala1  Georg Karpel-Massler1  Richard Eric Kast2  Christian Rainer Wirtz1  | |
[1] Department of Neurosurgery, University of Ulm School of Medicine, Steinhövelstrasse 9, Ulm D-89077, Germany; E-Mails:;Department of Psychiatry, University of Vermont, 22 Church Street, Burlington, VT 05401, USA; E-Mails: | |
关键词: epithelial to mesenchymal transition; glioblastoma multiforme; targeted therapy; epidermal growth factor receptor; EGFRvIII; tyrosine kinase; erlotinib; gefitinib; | |
DOI : 10.3390/cancers4020523 | |
来源: mdpi | |
【 摘 要 】
Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, is almost never curable with the current standard treatment consisting of surgical resection, irradiation and temozolomide. The prognosis remains poor despite undisputable advances in the understanding of this tumor’s molecular biology and pathophysiology, which unfortunately has so far failed to translate into a meaningful clinical benefit. Dysregulation and a resulting prominent pathophysiological role of the epidermal growth factor receptor (EGFR) have been identified in several different malignant tumor entities, GBM among them. The EGFR is overexpressed in about 40% of GBM cases, and half of these coexpress a mutant, constitutively activated subtype, EGFRvIII. Unfortunately, recent trials studying with therapeutic approaches targeted against the EGFR and EGFRvIII have failed to meet expectations, with only a minority of patients responding despite evidence of good
【 授权许可】
CC BY
© 2012 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190044598ZK.pdf | 263KB | download |